

Listing of the Claims:

1. (Currently amended) A method for producing a plurality of dendritic cell/tumor cell hybrids which induce an anti-tumor response when applied to a patient causing a reduction of the number of tumor cells in said patient, said method comprising:

(a) providing dendritic cells,

wherein said dendritic cells are selected from the group consisting of:
dendritic cells which are autologous with respect to said patient, dendritic cells which
are allogeneic with respect to said patient, and dendritic cells which are both
allogeneic with respect to said patient and HLA compatible with said patient, and
wherein said dendritic cells are either isolated from bone marrow, lymph or
blood, or are differentiated in vitro from dendritic cell precursors isolated from bone
marrow, lymph or blood, and

(b) fusing said dendritic cells with tumor cells to produce a plurality of
dendritic cell/tumor cell hybrids, wherein said dendritic cell is not a T-lymphocyte or
B-lymphocyte, wherein said tumor cell is selected from the group consisting of: an
autologous tumor cell with respect to said patient, and an allogeneic tumor cell
characteristic of the same cancer type with respect to said patient,

(c). selecting from said plurality of dendritic cell/tumor cell hybrids
that exhibit dendritic cell markers, tumor associated antigens and the capacity to
activate naïve T cells in vitro that can recognize the cancer cells of step (b).

~~(a) — providing a sample of a tumor against which said response is~~
~~needed,~~

~~(b) — preparing a primary cell culture comprising tumor cells derived~~
~~from said tumor sample,~~

~~(c) — providing autologous or HLA-compatible allogeneic dendritic cells~~
~~by isolation of dendritic cells from bone marrow, lymph or blood, or,~~
~~preparing said dendritic cells by differentiating in vitro proliferating~~
~~dendritic cell precursors isolated from bone marrow, lymph or blood, and,~~

~~(d) — fusing said dendritic cells with said tumor cells to produce a~~
~~plurality of hybrids, wherein said dendritic cell is not a T lymphocyte or B-~~
~~lymphocyte.~~

2. (Currently amended) The method of claim 1 wherein the dendritic cells of step (a)~~(e)~~ are produced by culturing said dendritic cell precursors in the presence of cytokines.
3. (Canceled)
4. (Canceled)
5. (Currently amended) The method of claim 1 wherein the dendritic cell of step (a)~~(e)~~ is of myeloid origin.
6. (Currently amended) The method of claim 1 wherein the dendritic cell of step (a)~~(e)~~ is of lymphoid origin.
7. (Currently amended) The method of claim 1 wherein the dendritic cell of step (a)~~(e)~~ is an isolated dendritic cell.
8. (Canceled)
9. (Currently amended) The method of claim 1 wherein said fusing ~~the fusion of step (d)~~ is carried out using PEG.
10. (Canceled)
11. (Canceled)
12. (Canceled)
13. (Canceled)
14. (Canceled)
15. (Cancelled)
16. (Canceled)
17. (Canceled)
18. (Canceled)
19. (Canceled)
20. (Canceled)
21. (Canceled)
22. (Canceled)
23. (Canceled)
24. (Canceled)
25. (Canceled)
26. (Canceled)
27. (Canceled)
28. (Canceled)

29. (Canceled)
30. (Canceled)
31. (Canceled)
32. (Canceled)
33. (Canceled)
34. (Currently amended) The method of claim 1 ~~31~~, wherein said tumor cells of step ~~(a)(e)~~ are ~~drug-sensitive~~ to a drug, said method further comprising, after step ~~(c)(e)~~, killing unfused ~~drug-sensitive-immortal~~ tumor cells by exposure to said drug.
35. (Original) The method according to claim 34 wherein said drug is hypoxanthine-aminopterin-thymidine (HAT).
36. (Canceled)
37. (Canceled))
38. (Canceled))
39. (Canceled)
40. (Canceled)
41. (Canceled)
42. (Currently amended) A method of claim 1 wherein the ~~obtained~~ plurality of dendritic cell/tumor cell hybrids is further induced to express ~~the~~ dendritic cell characteristics.
43. (Canceled)
44. (Canceled)
45. (Canceled)
46. (Original) A method of claim 42 wherein said induction is performed using GM-CSF, IFN, γ , TNF- α or a combination thereof.
47. (Canceled)
48. (Canceled)
49. (Canceled)
50. (Currently amended) A method of claim 1 wherein the plurality of dendritic cell/tumor cell hybrids ~~obtained hybrid~~ is treated to prevent further proliferation before using it for the induction of an anti-tumor response.
51. (Canceled)
52. (Canceled)
53. (Canceled)

- 54. (Original) A method of claim 50 wherein said treatment occurs by irradiation.
- 55. (Canceled)
- 56. (Canceled)
- 57. (Canceled)
- 58. (New) The method of claim 1, wherein the dendritic cells are from a dendritic-like cell line.
- 59. (New) The method of claim 1, wherein the tumor cells of step (b) are from a tumor cell line having at least one tumor associated antigen in common with said tumor sample.
- 60. (New) The method of claim 1, wherein the dendritic cell/tumor cell hybrids are hybridomas.
- 61. (New) The method of claim 58, wherein said tumor cells of step (b) are from said patient.
- 62. (New) The method of claim 59, wherein the tumor cell line is derived from tumor cells from said patient.
- 63. (New) The method of claim 59, wherein the tumor cell line is derived from tumor cells from said patient.
- 64. (New) The method of claim 1, wherein said dendritic cells are dendritic-like cells.
- 65. (New) The method of claim 1, wherein said tumor cell is an allogeneic tumor cell with respect to said patient, and has one or more tumor associated antigens in common with that of said autologous tumor cell.
- 66. (New) the method of claim 1, wherein said anti-tumor response comprises the in vivo induction of immune effectors that confer resistance to a subsequent challenge with tumor cells.